Virax Biolabs Group Limited (VRAX)

Name: Virax Biolabs Group Limited Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-09-30

Latest Quarter

2025-09-30

Revenue

$1.6K

Net Income

-$2.3M

Operating Margin

-160,788.2%

Free Cash Flow

-$5.2M

Debt / Assets

15.0%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Virax Biolabs Group Limited (VRAX).
Income Statement (Quarterly)	2025-09-30	2024-09-30	2024-03-31	2023-09-30
Revenue	1,608	4,953	79,919	76,500
Cost of Revenue	217,022	11,427	39,847	65,982
Gross Profit	-215,414	-6,474	40,072	10,518
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	990,316	2,146,005	2,287,297	2,307,446
Operating Expenses	2,370,061	2,872,417	3,830,322	2,716,741
Operating Income	-2,585,475	-2,878,891	-3,790,250	-2,706,220
Interest Expense	30,991	0	16,764	10,114
Income Before Tax	-2,616,867	-2,893,225	-3,824,916	-2,914,204
Income Tax Expense	-273,594	-136,661	0	-4,551
Net Income	-2,338,771	-2,756,427	-3,823,885	-2,909,652
Per Share
EPS	-0.49	-0.89	-1.71	-1.64
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Virax Biolabs Group Limited (VRAX).
Income Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Revenue	6,331	156,419	8,561	0	123,820
Cost of Revenue	59,398	105,829	9,926	0	133,254
Gross Profit	-53,067	50,590	-1,365	0	-9,434
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	4,330,028	4,594,743	5,334,287	1,299,936	514,883
Operating Expenses	6,109,830	6,547,063	5,731,396	1,733,679	635,104
Operating Income	-6,162,897	-6,496,473	-5,732,760	-1,733,680	-644,538
Interest Expense	58,179	26,878	15,468	15,438	28,643
Income Before Tax	-6,203,893	-6,739,120	-5,457,763	-1,749,870	-672,915
Income Tax Expense	-136,661	0	-271	-1,774,722	0
Net Income	-6,061,247	-6,733,537	-5,457,494	-1,708,827	-650,984
Per Share
EPS	-1.96	-3.36	-5.13	-1.50	-0.06
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Virax Biolabs Group Limited (VRAX).
Balance Sheet (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Assets
Cash and Cash Equivalents	4,228,944	3,589,244	9,352,538	21,756
Short Term Investments	0	77,321	49,257	5,999
Net Receivables	30,654	217,843	-24,095	0
Inventory	94,675	60,383	24,095	20,951
Total Current Assets	4,893,655	4,380,252	9,634,013	48,706
Property Plant Equipment	1,533,248	1,103,717	0	0
Goodwill and Intangibles	39,652	49,771	178,403	0
Total Assets	6,426,903	5,483,969	9,812,416	48,706
Liabilities
Account Payables	56,093	45,631	159,908	846,474
Short Term Debt	85,461	47,955	146,250	3,758
Total Current Liabilities	673,207	168,849	908,401	1,245,414
Long Term Debt	291,543	176,345	0	0
Total Liabilities	964,750	345,194	908,401	1,245,414
Shareholders Equity
Retained Earnings	-24,589,244	-18,527,997	-11,794,460	-6,336,966
Total Shareholders Equity	5,696,120	5,366,757	9,126,414	-974,578

Balance sheet annual history for Virax Biolabs Group Limited (VRAX).
Balance Sheet (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Assets
Cash and Cash Equivalents	4,228,944	3,589,244	9,352,538	21,756	17,621
Short Term Investments	0	77,321	49,257	5,999	0
Net Receivables	30,654	217,843	-24,095	0	928
Inventory	94,675	60,383	24,095	20,951	21,072
Total Current Assets	4,893,655	4,380,252	9,634,013	48,706	39,621
Property Plant Equipment	1,533,248	1,103,717	0	0	0
Goodwill and Intangibles	39,652	49,771	178,403	0	0
Total Assets	6,426,903	5,483,969	9,812,416	48,706	39,621
Liabilities
Account Payables	56,093	45,631	159,908	846,474	217,145
Short Term Debt	85,461	47,955	146,250	3,758	0
Total Current Liabilities	673,207	168,849	908,401	1,245,414	871,435
Long Term Debt	291,543	176,345	0	0	0
Total Liabilities	964,750	345,194	908,401	1,245,414	871,435
Shareholders Equity
Retained Earnings	-24,589,244	-18,527,997	-11,794,460	-6,336,966	-4,628,139
Total Shareholders Equity	5,696,120	5,366,757	9,126,414	-974,578	-650,682

Cash flow quarterly history for Virax Biolabs Group Limited (VRAX).
Cash Flow Statement (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Activities
Net Income	-6,067,232	-6,739,120	-5,457,494	-1,708,827
Depreciation & Amortization	343,387	103,099	0	0
Stock Based Compensation	365,309	1,011,973	1,734,601	287,442
Change in Working Capital	625,617	-1,120,029	-216,275	644,390
Operating Cash Flow	-4,563,576	-6,247,016	-4,179,767	-809,069
Investing Activities
Capital Expenditure	-603,890	-1,164,449	-178,403	0
Investments	-603,890	-952,497	-178,403	0
Investing Cash Flow	-603,890	-1,164,449	-178,403	0
Financing Activities
Debt Repayment	-107,756	-206,272	-146,250	0
Common Stock Issued/Repurchased	5,128,186	234	13,654,347	519,613
Dividends Paid	0	0	0	0
Financing Cash Flow	5,807,166	1,648,171	13,688,952	813,205
Summary
Free Cash Flow	-5,167,466	-7,411,465	-4,358,170	-809,069
Net Change in Cash	639,700	-5,763,294	9,330,782	4,135

Cash flow annual history for Virax Biolabs Group Limited (VRAX).
Cash Flow Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Operating Activities
Net Income	-6,067,232	-6,739,120	-5,457,494	-1,708,827	-650,984
Depreciation & Amortization	343,387	103,099	0	0	0
Stock Based Compensation	365,309	1,011,973	1,734,601	287,442	0
Change in Working Capital	625,617	-1,120,029	-216,275	644,390	59,611
Operating Cash Flow	-4,563,576	-6,247,016	-4,179,767	-809,069	-590,186
Investing Activities
Capital Expenditure	-603,890	-1,164,449	-178,403	0	0
Investments	-603,890	-952,497	-178,403	0	0
Investing Cash Flow	-603,890	-1,164,449	-178,403	0	0
Financing Activities
Debt Repayment	-107,756	-206,272	-146,250	0	0
Common Stock Issued/Repurchased	5,128,186	234	13,654,347	519,613	0
Dividends Paid	0	0	0	0	0
Financing Cash Flow	5,807,166	1,648,171	13,688,952	813,205	585,198
Summary
Free Cash Flow	-5,167,466	-7,411,465	-4,358,170	-809,069	-590,186
Net Change in Cash	639,700	-5,763,294	9,330,782	4,135	-4,988